MedTrace Logo

Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer

NCT06654622 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 175

Last updated 2026-03-13

No results posted yet for this study

Summary

This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for more personalized treatment approaches and potentially improving patient outcomes.

Conditions

  • Colo-rectal Cancer
  • Colorectal Cancer Recurrent

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Ajay Goel, PhD · City of Hope Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2026-01-18
Completion
2026-02-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06654622 on ClinicalTrials.gov